2283387-37-9
Chemical Structure
Ligusticum cycloprolactam
- CAS No.: 2283387-37-9
- Formula:C15H21NO2
- Molecular Weight:247.33
InChIKey: UGJKCMVDJPXTBF-UHFFFAOYSA-N
SMILES: O=C1C2=C(C(N1C3CC3)(CCCC)O)CCC=C2
Biological Activity: Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ligusticum cycloprolactam | Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Gao J, et al. A Novel Compound Ligusticum Cycloprolactam Alleviates Neuroinflammation After Ischemic Stroke via the FPR1/NLRP3 Signaling Axis. CNS Neurosci Ther. 2024;30(12):e70158. [Content Brief]
- [2]. Chen Z, et al. Ligusticum cycloprolactam ameliorates hyperuricemic nephropathy through inhibition of TLR4/NF-κB signaling. J Nutr Biochem. 2025;139:109864. [Content Brief]
- [3]. Gao J, et al. Mechanism of ligusticum cycloprolactam against neuroinflammation based on network pharmacology and experimental verification. Clin Exp Pharmacol Physiol. 2023;50(8):647-663. [Content Brief]
- [4]. Yongqi Yang, et al. IDDF2024-ABS-0318 Ligusticum cycloprolactam (LIGc), a novel FXR agonist: target activation of FXR ameliorate metabolic associated fatty liver disease. Gut 2024;73(Suppl 2):A1-A398.
Keywords
